These findings highlight the importance of the LASS2-MDM2/MDMX-p53 signaling axis in the regulation of liver cancer and may elucidate the mechanisms of mutant p53 reactivation, providing possible new targets for clinical treatment. The gene discussed is CERS2; the disease is liver cancer.